Cerus (NASDAQ:CERS) Announces Quarterly Earnings Results, Meets Expectations

Cerus (NASDAQ:CERS) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01), FiscalAI reports. The business had revenue of $63.30 million during the quarter, compared to analysts’ expectations of $62.90 million. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%.

Here are the key takeaways from Cerus’ conference call:

• Q2 product revenue rose 10% to $57.4 million, while first-half revenue increased 16% year over year. Cerus raised the low end of its 2026 product revenue guidance to $229 million–$231 million, implying 11%–12% annual growth.
• INTERCEPT fibrinogen complex (IFC) revenue grew approximately 40% excluding prior-period revenue, with demand up 43%; Cerus raised its 2026 IFC revenue outlook to $23 million–$25 million. The company cited growing hospital adoption, BCA collaboration, and the product’s immediate availability and five-day post-thaw shelf life.
• Cerus refinanced its debt, reducing the term loan by $30 million and expecting to lower annual interest expense by up to $3.5 million. Adjusted EBITDA remained positive for the ninth consecutive quarter, and management said it has a path toward GAAP profitability.
• Product gross margin declined to 51.4% from 55.2% a year earlier due to currency and inflationary pressures; management expects full-year 2026 margins to remain in the low 50% range. Operating cash flow was negative $2.7 million, primarily because of higher inventory supporting expected growth.
• The company submitted its INT200 platelet PMA to the FDA and could receive approval as early as the first half of 2027. Cerus also expects Phase III INTERCEPT red blood cell trial results in the fourth quarter and expanded its BARDA contract by nearly $22 million to support U.S. regulatory activities.

Cerus Stock Performance

CERS traded down $0.75 during trading on Friday, hitting $2.14. The stock had a trading volume of 6,505,178 shares, compared to its average volume of 2,159,107. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.63 and a quick ratio of 1.06. The company has a 50 day moving average price of $2.87 and a 200-day moving average price of $2.43. Cerus has a one year low of $1.15 and a one year high of $3.47. The firm has a market cap of $429.19 million, a price-to-earnings ratio of -42.50 and a beta of 1.77.

Wall Street Analyst Weigh In

Several analysts have issued reports on CERS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a research report on Thursday, June 18th. Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Zacks Research upgraded Cerus from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. Finally, BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a report on Friday, May 1st. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.00.

Insider Activity

In related news, Director Eric Bjerkholt sold 20,454 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $2.60, for a total value of $53,180.40. Following the transaction, the director directly owned 261,679 shares in the company, valued at approximately $680,365.40. This represents a 7.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Vivek K. Jayaraman sold 42,359 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total transaction of $124,535.46. Following the transaction, the chief operating officer directly owned 1,694,348 shares in the company, valued at approximately $4,981,383.12. This represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 239,404 shares of company stock worth $697,893. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Cerus

A number of institutional investors have recently bought and sold shares of CERS. Vanguard Group Inc. grew its position in shares of Cerus by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock worth $17,147,000 after purchasing an additional 62,663 shares in the last quarter. Wasatch Advisors LP raised its position in shares of Cerus by 2.6% in the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock valued at $12,033,000 after buying an additional 213,917 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Cerus by 17.6% in the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock valued at $5,517,000 after buying an additional 519,301 shares during the period. Ieq Capital LLC boosted its stake in shares of Cerus by 1.1% in the fourth quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock valued at $4,993,000 after buying an additional 25,771 shares during the period. Finally, AQR Capital Management LLC grew its position in Cerus by 291.6% during the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after buying an additional 1,064,133 shares in the last quarter. Institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.